💊 = pharma ties / conflict of interest

Almohanna HM, Perper M, Tosti A 💊 [COIs]. Safety concerns when using novel medications to treat alopecia. Expert Opin Drug Saf. 2018. doi:10.1080/14740338.2018.1533549 • PubMed

Badri T, Nessel TA, Kumar D. Minoxidil. StatPearls; 2021. Available from: NCBI Bookshelf

Baldini S, Khattak A, Capogrosso P, et al. The possible role of prescribing medications, including central nervous system drugs, in contributing to male-factor infertility (MFI): assessment of the Food and Drug Administration (FDA) pharmacovigilance database. Brain Sci. 2023. doi:10.3390/brainsci13121652• PubMed

da Cruz GK, Martins MIM, Antunes FTT, et al. Evaluation of the efficacy and toxicity of oral and topical pumpkin oil on the hair growth of mice. Acta Histochem. 2022. doi:10.1016/j.acthis.2022.151894 • PubMed

“Minoxidil increased the DNA damage in the blood and the liver tissues.”

Donovan DJ. Paresthesias from topical minoxidil: Are we missing it? Donovan Hair Clinic [dermatologist’s blog post]. donovanmedical.com/hair-blog/minoxidil-paresthesias

Ersland E, Ebrahim N, Mwizerwa O, et al. Human vascular wall microfluidic model for preclinical evaluation of drug-induced vascular injury. Tissue Eng Part C Methods. 2022. doi:10.1089/ten.TEC.2021.0227 • PubMedi

Minoxidil has “demonstrated preclinical drug-induced vascular injury but lack[s] clinical evidence… [M]inoxidil demonstrated minor endothelial cell barrier injury but damaged vascular smooth muscle cells…”

González M, Landa N, Gardeazabal J, Calderón MJ, Bilbao I, Díaz Pérez JL. Generalized hypertrichosis after treatment with topical minoxidil. Clin Exp Dermatol. 1994. doi:10.1111/j.1365-2230.1994.tb01147.x • PubMed

Hsu CL, Liu JS, Lin AC, Yang CH, Chung WH, Wu WG. Minoxidil may suppress androgen receptor-related functions. Oncotarget. 2014. doi:10.18632/oncotarget.1886 • PubMed • PMC full text

Korbi M, Said El Mabrouk R, Abdelaali M, Youssef M, Belhadjali H, Zili J. Topical minoxidil-induced paresthesia. Dermatol Ther. 2022. doi:10.1111/dth.15328 • PubMed

Mazen A. Topical minoxidil 5% induced male sexual dysfunction. Indian Journal of Medical Research and Pharmaceutical Sciences. 2017. doi:10.5281/zenodo.580856

Mir-Bonafé JF, Mir-Bonafé M, Rozas-Muñoz E, Mir-Bonafé JM. Morning periorbital edema related to low-dose oral minoxidil. Actas Dermosifiliogr. 2022. English, Spanish. doi:10.1016/j.ad.2021.09.010 • PubMed • PDF in English (automated translation) • PDF in Spanish

Moreno-Arrones OM, Rodrigues-Barata R, Morales C, et al. Serious adverse effects from compounding errors with low-dose oral minoxidil for alopecia treatment. Actas Dermosifiliogr. 2022. English, Spanish. doi:10.1016/j.ad.2021.03.003PubMed

Pekmezci E, Türkoğlu M. Minoxidil acts as an antiandrogen: a study of 5α-reductase type 2 gene expression in a human keratinocyte cell line. Acta Dermatovenerol Croat. 2017. PubMed

Santana FFV, Lozi AA, Gonçalves RV, Da Silva J, Da Matta SLP. Comparative effects of finasteride and minoxidil on the male reproductive organs: a systematic review of in vitro and in vivo evidence. Toxicol Appl Pharmacol. 2023. doi:10.1016/j.taap.2023.116710 • PubMed

Sinclair RD, Mallari RS, Tate B. Sensitization to saw palmetto and minoxidil in separate topical extemporaneous treatments for androgenetic alopecia. Australas J Dermatol. 2002. doi:10.1046/j.1440-0960.2002.00620.x • PubMed

Trüeb RM, Caballero-Uribe N. Minoxidil-induced hypertrichosis in a breastfed infant. J Eur Acad Dermatol Venereol. 2022. doi:10.1111/jdv.17755 • PubMed

Tsoporis J, Keeley FW, Lee RM, Leenen FH. Arterial vasodilation and vascular connective tissue changes in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1998. doi:10.1097/00005344-199806000-00022 • PubMed

Elsewhere online

Post Minoxidil Syndrome | RxISK

Subreddit: r/MinoxidilSideEffectsWiki